Skip to main content
Clinical Trials/NCT06487650
NCT06487650
Not yet recruiting
Not Applicable

The Development and Evaluation of Sleep Intervention for Perinatal Family

Taipei Medical University0 sites600 target enrollmentDecember 2025

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sleep
Sponsor
Taipei Medical University
Enrollment
600
Primary Endpoint
Insomnia Severity Index
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

Background: Sleep disruptions and disturbances are highly prevalent among new mothers and fathers and negatively affect their mental health and infant development outcomes. Effective sleep interventions are vital for family health.

Objectives: To develop a sleep intervention for mother-father-infant triads, and to evaluate the effects on sleep improvement, emotional distress, and infant health outcomes.

Methods: In this proposal, we plan to conduct a parallel-group two-arm randomized controlled trial on pregnant women and their partners. Mother-father-infant triads will be recruited and randomly allocated to the intervention group (receiving a sleep intervention) or the control group. Data will be collected with repeated measures, and the relationship between studied variables will be analyzed with descriptive and inferential statistics.

Anticipatory results: The development and evaluation of an evidence-based sleep intervention will provide a scientific insight into sleep care for pregnant women and their families.

Detailed Description

The primary outcome is the severity of insomnia symptoms. The secondary outcomes of parents' sleep quality, objective sleep indicators, symptoms of depression and anxiety, and heart rate variability will be collected. Infant sleep quality, infant feeding, and infant health outcomes will also be assessed. Data will be analyzed using descriptive and inferential statistics.

Registry
clinicaltrials.gov
Start Date
December 2025
End Date
September 2026
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • First-time mothers and their partners aged 20 and older;
  • Currently 30 weeks gestation or more, singleton;
  • insomnia severity index score greater than 10;
  • living with a husband or partner;
  • Both women and their partners are willing to participate in and adhere to the research protocol;
  • be able to read and speak the Mandarin language

Exclusion Criteria

  • sleep disorders, depression or anxiety disorders;
  • medical diseases with abnormal heart rate variability, or arrhythmia;
  • taking medicines that may affect the autonomic nervous system or
  • night shift workers;
  • obstetric complications, including gestational hypertension, preterm labor, labor complications, or postpartum complications;
  • infants with fetal deformity, or neonatal complications;
  • no access to Internet resources

Outcomes

Primary Outcomes

Insomnia Severity Index

Time Frame: baseline, at 36-weeks' gestation, 2-week postpartum, 1-month, 3-month,6-month, and 12-month postpartum

The Chinese version of the Insomnia Severity Index (ISI) is used to measure the severity of insomnia symptoms, a higher score indicates more severe insomnia symptoms.

Secondary Outcomes

  • Sleep efficacy using actigraphy(baseline, postpartum 1 month, 3 months, and 6 months.)
  • Infants sleep Questionnaire(postpartum 1 month, 3 months, 6 months, and 12-months)
  • Heart rate variability (HRV) measures(at baseline, postpartum 1 month, 3 months, and 6 months)
  • Sleep duration using actigraphy(baseline, postpartum 1 month, 3 months, and 6 months.)
  • Wake after sleep onset using actigraphy(baseline, postpartum 1 month, 3 months, and 6 months.)
  • Infant height(postpartum 3 months, 6 months, and 12-months)
  • Satisfaction of sleep intervention(immediately after interventions)
  • Sleep sleep onset latency using actigraphy(baseline, postpartum 1 month, 3 months, and 6 months.)
  • Sleep quality(baseline, at 36-weeks' gestation, postpartum 1 month, 3 months, 6 months, and 12-months)
  • Depressive symptoms(baseline, at 36-weeks' gestation, postpartum 1 month, 3 months, 6 months, and 12-months)
  • Anxiety symptoms(baseline, at 36-weeks' gestation, postpartum 1 month, 3 months, 6 months, and 12-months)
  • Infant feeding(postpartum 1 month, 3 months, and 6 months, and 12 months)
  • Infant weight(postpartum 3 months, 6 months, and 12-months)
  • Infant development(postpartum 3 months, 6 months, and 12-months)

Similar Trials